An Oral Mucosa‐Inspired Wet‐Adhesion Janus Hydrogel With Asymmetric Bifunctionalities of Antifouling/Antioxidant for Treating Oral Ulcer in Diabetes

Why It Matters

The technology addresses the persistent challenge of healing wet, inflamed diabetic oral lesions, offering a clinically viable solution that could reduce complications and healthcare costs.

Key Takeaways

• Janus hydrogel adheres strongly to wet ulcer surfaces
• Antifouling layer prevents bacterial colonization
• Tannic acid provides ROS scavenging antioxidant effect
• Adhesion energy reaches 316 J m⁻², far exceeding antifouling side
• In diabetic models, healing time reduced significantly

Pulse Analysis

The WAJH hydrogel leverages a biomimetic design that separates protective and adhesive functions into two distinct layers. By replicating the oral epithelium with an agar/polyacrylamide double‑network, the antifouling side creates a barrier against microbial invasion, a critical factor in diabetic patients whose immune response is compromised. Meanwhile, the poly(acrylic acid‑co‑2‑phenoxyethyl acrylate) matrix infused with tannic acid forms a robust wet‑adhesive interface, achieving adhesion energies comparable to natural basement membranes and ensuring the dressing remains in place despite saliva flow.

Beyond mechanical performance, the incorporation of tannic acid endows the hydrogel with potent antioxidant properties. Reactive oxygen species are a major driver of chronic inflammation in diabetic ulcers; the hydrogel’s ROS‑scavenging capability mitigates oxidative stress, thereby dampening inflammatory cytokine release. This biochemical environment supports rapid angiogenesis, as new blood vessels form to supply nutrients and oxygen essential for tissue regeneration. The dual action of fouling resistance and oxidative protection creates a synergistic platform that accelerates re‑epithelialization and restores mucosal integrity.

Clinical translation of WAJH could reshape management protocols for oral complications in diabetes, a condition affecting over 400 million people worldwide. Traditional treatments—ranging from topical antibiotics to conventional dressings—often fail to adhere in the moist oral cavity and may exacerbate inflammation. WAJH’s wet‑adhesion and bioactive functions promise fewer dressing changes, reduced infection risk, and shorter healing timelines, translating into lower treatment costs and improved patient quality of life. As regulatory pathways for advanced wound‑care biomaterials mature, this mucosa‑inspired hydrogel positions itself as a next‑generation therapeutic for a high‑need patient population.